Click Here to
Subscribe
Breaking
News, Updates,
& More
Stay Up
to Date
Venous thromboembolism (VTE) is a major complication of hematologic malignancies and is associated with significant morbidity and mortality. Patients with multiple myeloma are especially at risk for VTEs based on the underlying disease pathophysiology and the treatments used for this patient population, specifically immunomodulatory drugs (IMiDs). The risk for VTE among patients ranges from 26% to 67% for those with newly diagnosed multiple myeloma, and from 11% to 15% for patients with relapsed or refractory multiple myeloma. The use of IMiDs further increases the risk for thromboembolic complications, particularly within the first 6 months of therapy, although this risk decreases over time.
Cisplatin is a platinum-based antineoplastic drug that is widely prescribed alone or in combination for the treatment of patients with solid-organ tumors.
Myelosuppression is a dose-limiting complication of systemic chemotherapy that can result in serious and life-threatening infections.
Tumor lysis syndrome (TLS) is a life-threatening complication of hematologic malignancies and some solid tumors. This syndrome occurs after tumor cells break down spontaneously or after exposure to radiation or chemotherapy. Lysis of tumor cells will release intracellular contents into the bloodstream, leading to hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia.
The use of a closed-system transfer device (CSTD) has been accepted as a standard of practice to minimize exposure to harmful materials when compounding hazardous medications. Several reports indicate that CSTDs also preserve the sterility of unpreserved (ie, single-use) medication vials for up to 1 week. Taking advantage of prolonged sterility of nonpreserved vials with an appropriate CSTD attached offers the possibility of significant cost-savings through reduced drug waste.
Ovarian cancer is the leading cause of death among gynecologic tumors.
Pharmacists play a vital role in ensuring the safe administration of medications.
Nathan M. Kawamura, PharmD, BCOP, and colleagues assess the reasons for dose reductions and treatment discontinuation in patients who receive oral chemotherapy for metastatic kidney cancer.

This single-institution study led by Caroline Townley, PharmD, compares the use of the Onpro device and the manual injection of pegfilgrastim and discusses the potential implications of the findings.

Ákos Juhász, PharmD, and colleagues suggest that the use of a closed-system drug-transfer device would reduce the high levels of contamination found in hospital pharmacies.

Page 1 of 6
Results 1 - 10 of 53